

Humira® Coverage Determination Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		Office Contact:
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name: Select one of the following: <input type="checkbox"/> Request is for GENERIC <input type="checkbox"/> Request is for BRAND (unable to take the generic)			Strength:		Dosage Form:
<input type="checkbox"/> Check if request is for continuation of therapy			Directions for Use:		
Clinical Information <small>(required)</small>					
Select the Type(s) of Coverage Determination Requested:					
<input type="checkbox"/> Prior Authorization - Request is for a drug that requires prior authorization under the plan.					
<input type="checkbox"/> Quantity Limit - Request is for an exception to the plan's quantity limit. Quantity requested: _____					
Select the diagnosis below:					
<input type="checkbox"/> Ankylosing spondylitis (AS)		<input type="checkbox"/> Moderate-to-severe rheumatoid arthritis			
<input type="checkbox"/> Crohn's disease (CD)		<input type="checkbox"/> Non-infectious intermediate, posterior, or pan-uveitis			
<input type="checkbox"/> Hidradenitis suppurativa		<input type="checkbox"/> Psoriatic arthritis (PsA)			
<input type="checkbox"/> Moderate-to-severe juvenile idiopathic arthritis (JIA)		<input type="checkbox"/> Ulcerative colitis			
<input type="checkbox"/> Moderate to severe plaque psoriasis					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Clinical Information:					
Is there documentation the patient has been evaluated for active or latent tuberculosis (TB)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will the patient receive Humira concurrently with any other biologic disease modifying anti-rheumatic drugs (DMARDs) (e.g., tumor necrosis factor antagonists)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if Humira is prescribed by one of the following specialists:					
<input type="checkbox"/> Dermatologist		<input type="checkbox"/> Ophthalmologist			
<input type="checkbox"/> Gastroenterologist		<input type="checkbox"/> Rheumatologist			
For new starts only: Have at least two weeks passed since the administration of the Herpes Zoster vaccine prior to the start of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, or rheumatoid arthritis, also answer the following:					
Select if there is documentation the patient has had an inadequate response or inability to tolerate the following:					
<input type="checkbox"/> Azathioprine		<input type="checkbox"/> Leflunomide		<input type="checkbox"/> Remicade (infliximab)	
<input type="checkbox"/> Hydroxychloroquine		<input type="checkbox"/> Methotrexate		<input type="checkbox"/> Sulfasalazine	
For Crohn's disease or ulcerative colitis, also answer the following:					
Select if there is documentation the patient has had an inadequate response or inability to tolerate the following:					
<input type="checkbox"/> Aminosalicylate					
<input type="checkbox"/> Corticosteroids					
<input type="checkbox"/> Immunomodulators (e.g., azathioprine, 6-mercaptopurine)					
<input type="checkbox"/> Remicade (infliximab)					



Humira[®] Coverage Determination Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For hidradenitis suppurativa, also answer the following:

Is there documentation the patient has had an inadequate response or inability to tolerate Remicade (infliximab)? Yes No

For non-infectious intermediate, posterior, or pan-uveitis, also answer the following:

Select if there is documentation the patient has had an inadequate response or inability to tolerate the following:

- One oral corticosteroid
- One topical ophthalmic steroid
- Remicade (infliximab)

For plaque psoriasis, also answer the following:

Select if there is documentation the patient has had an inadequate response or inability to tolerate the following:

- Remicade (infliximab)
- Topical immunomodulators (Elidel, Protopic)
- Topical anthralin
- Topical retinoids
- Topical calcipotriene containing products
- Topical steroids

Quantity Limit Requests:

Is there a high risk of significant adverse clinical outcome with medication change or dosage change? Yes No

Is the requested quantity and dose within FDA approved maximum dosing limits or supported by peer-reviewed medical literature, accepted standards of medical practice and/or medical compendia? Yes No

If **yes**, please specify: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.